Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.

Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC.

Drug Alcohol Depend. 2009 Nov 1;105(1-2):154-9. doi: 10.1016/j.drugalcdep.2009.07.001. Epub 2009 Aug 3.

PMID:
19647958
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.

Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC.

J Pharmacol Exp Ther. 2014 Feb;348(2):217-26. doi: 10.1124/jpet.113.209478. Epub 2013 Nov 13.

PMID:
24227768
[PubMed - indexed for MEDLINE]
3.

Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN.

Drug Alcohol Depend. 1998 Mar 1;50(1):1-8.

PMID:
9589267
[PubMed - indexed for MEDLINE]
4.

The Clinical Opiate Withdrawal Scale (COWS).

Wesson DR, Ling W.

J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9. Review.

PMID:
12924748
[PubMed - indexed for MEDLINE]
5.

Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Holbrook AM, Jones HE, Heil SH, Martin PR, Stine SM, Fischer G, Coyle MG, Kaltenbach K.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):329-34. doi: 10.1016/j.drugalcdep.2013.02.031. Epub 2013 Mar 21.

PMID:
23523131
[PubMed - indexed for MEDLINE]
6.

Use of naloxone in the assessment of opiate dependence.

Fudala PJ, Berkow LC, Fralich JL, Johnson RE.

Life Sci. 1991;49(24):1809-14.

PMID:
1943484
[PubMed - indexed for MEDLINE]
7.

A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.

Setnik B, Roland CL, Goli V, Sommerville K, Webster L.

J Opioid Manag. 2013 Mar-Apr;9(2):139-50. doi: 10.5055/jom.2013.0155.

PMID:
23709323
[PubMed - indexed for MEDLINE]
8.

[Clinical assessment of physical dependence potential of dihydroetorphine hydrochloride (DHE)].

Ge Y, Li M, Sun WL, Cai ZJ.

Yao Xue Xue Bao. 1994;29(4):256-60. Chinese.

PMID:
7976340
[PubMed - indexed for MEDLINE]
9.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
[PubMed - indexed for MEDLINE]
10.

Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.

Chopra MP, Feldman Z, Mancino MJ, Oliveto A.

Pharmacol Biochem Behav. 2008 Oct;90(4):787-96. doi: 10.1016/j.pbb.2008.05.023.

PMID:
18585405
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Modest opioid withdrawal suppression efficacy of oral tramadol in humans.

Lofwall MR, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2007 Oct;194(3):381-93. Epub 2007 Jul 1.

PMID:
17605004
[PubMed - indexed for MEDLINE]
12.

Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Strain EC, Harrison JA, Bigelow GE.

Clin Pharmacol Ther. 2011 Mar;89(3):443-9. doi: 10.1038/clpt.2010.352. Epub 2011 Jan 26.

PMID:
21270789
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria.

Kosten TA, Jacobsen LK, Kosten TR.

Am J Drug Alcohol Abuse. 1989;15(3):237-50.

PMID:
2763981
[PubMed - indexed for MEDLINE]
14.

Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.

Walsh SL, Strain EC, Bigelow GE.

Addiction. 2003 Apr;98(4):427-39.

PMID:
12653813
[PubMed - indexed for MEDLINE]
15.

Pupillometric changes during gradual opiate detoxification correlate with changes in symptoms of opiate withdrawal as measured by the Weak Opiate Withdrawal Scale.

Rosse RB, Johri S, Goel M, Rahman F, Jawor KA, Deutsch SI.

Clin Neuropharmacol. 1998 Sep-Oct;21(5):312-5.

PMID:
9789712
[PubMed - indexed for MEDLINE]
16.

Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.

Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2006 Dec;189(3):297-306. Epub 2006 Sep 30.

PMID:
17013637
[PubMed - indexed for MEDLINE]
17.

Initial methadone dose in treating opiate addiction.

Wang RI, Kochar C, Hasegawa AT, Roh BL.

Int J Addict. 1982 Feb;17(2):357-63.

PMID:
7076369
[PubMed - indexed for MEDLINE]
18.

The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.

Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW.

Psychopharmacology (Berl). 2001 Aug;157(1):1-10.

PMID:
11512037
[PubMed - indexed for MEDLINE]
19.

Two new rating scales for opiate withdrawal.

Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD.

Am J Drug Alcohol Abuse. 1987;13(3):293-308.

PMID:
3687892
[PubMed - indexed for MEDLINE]
20.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk